C Lindén1, E Nuija, A Alm. 1. Department of Ophthalmology, Umeå University, Sweden.
Abstract
AIMS: To evaluate whether long-term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment. METHODS: Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 micrograms/ml once daily for 6-12 months. In 26 patients IOP was followed for 14 days after withdrawal of treatment. Aqueous flare was measured with a laser flare meter during 6-12 months' treatment in 16 patients. RESULTS: On the last day of treatment IOP was 6.9 mm Hg (95% CI 5.3-8.5) lower than before treatment. It increased slowly during the follow up period but was still 1.3 mm Hg (95% CI 0.2-2.5) lower than pretreatment IOP 14 days after cessation of treatment. No change in aqueous flare was seen throughout the study. CONCLUSION: Latanoprost has no clinically significant effect on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks, indicating that latanoprost is safe for long-term treatment.
AIMS: To evaluate whether long-term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment. METHODS:Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 micrograms/ml once daily for 6-12 months. In 26 patients IOP was followed for 14 days after withdrawal of treatment. Aqueous flare was measured with a laser flare meter during 6-12 months' treatment in 16 patients. RESULTS: On the last day of treatment IOP was 6.9 mm Hg (95% CI 5.3-8.5) lower than before treatment. It increased slowly during the follow up period but was still 1.3 mm Hg (95% CI 0.2-2.5) lower than pretreatment IOP 14 days after cessation of treatment. No change in aqueous flare was seen throughout the study. CONCLUSION:Latanoprost has no clinically significant effect on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks, indicating that latanoprost is safe for long-term treatment.
Authors: Jayaganesh V Natarajan; Sujay Chattopadhyay; Marcus Ang; Anastasia Darwitan; Selin Foo; Ma Zhen; Magdalene Koo; Tina T Wong; Subbu S Venkatraman Journal: PLoS One Date: 2011-09-09 Impact factor: 3.240
Authors: Jayaganesh V Natarajan; Marcus Ang; Anastasia Darwitan; Sujay Chattopadhyay; Tina T Wong; Subbu S Venkatraman Journal: Int J Nanomedicine Date: 2012-01-05